Repligen (NASDAQ:RGEN) Releases Earnings Results, Beats Expectations By $0.09 EPS

Repligen (NASDAQ:RGEN) posted its quarterly earnings data on Tuesday. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09, FiscalAI reports. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same period in the prior year, the firm earned $0.26 EPS. Repligen’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen updated its FY 2026 guidance to 2.030-2.090 EPS.

Repligen Trading Down 0.7%

Shares of Repligen stock opened at $131.06 on Tuesday. Repligen has a 1 year low of $100.99 and a 1 year high of $175.77. The company’s fifty day simple moving average is $132.21 and its 200-day simple moving average is $132.05. The company has a market cap of $7.39 billion, a price-to-earnings ratio of 145.62, a PEG ratio of 2.54 and a beta of 1.06. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.60% of the stock is currently owned by insiders.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UMB Bank n.a. raised its position in shares of Repligen by 13.8% during the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 92 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after buying an additional 100 shares in the last quarter. Itau Unibanco Holding S.A. increased its stake in Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 104 shares during the period. Cerity Partners LLC increased its stake in Repligen by 6.1% during the fourth quarter. Cerity Partners LLC now owns 2,718 shares of the biotechnology company’s stock valued at $445,000 after acquiring an additional 157 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in Repligen by 15.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,327 shares of the biotechnology company’s stock valued at $221,000 after acquiring an additional 175 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 14th. Jefferies Financial Group restated a “hold” rating and set a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. Wolfe Research initiated coverage on Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target on the stock. Roth Capital initiated coverage on Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective on the stock. Finally, Citigroup raised Repligen to a “buy” rating in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $165.36.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.